Previous studies have shown that protumorigenic macrophages are recruited to tumors via the CCR5‐CCL5 signaling axis, and that blocking this pathway with CCR5 antagonists has improved clinical outcomes in cancer patients [53, 64, 65, 66]. The gene discussed is CCL5; the disease is cancer.